Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
March 7, 2023
Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will...